9544.Se
The company operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, generating revenue primarily through its operations in this field.
Business. The company operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, generating revenue primarily through its operations in this field.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare sector, specializing in biotechnology and providing healthcare facilities and services, generating revenue primarily through its operations in this field.
The company maintains a strong liquidity position, with a current ratio of 9.3, indicating a high ability to meet short-term obligations. The liquidity_fpt metric further supports this, showing a robust cash and equivalents position of 20,595,360. The company's operating cash flow of 12,540,200 and free cash flow of 14,623,190 reinforce its financial flexibility.
Profitability metrics show the company is performing well relative to industry standards. The return on equity of 16.25% and return on assets of 14.23% are strong indicators of efficient capital use and asset management. The operating income of 17,612,660 and net income of 15,753,370 reflect solid earnings performance.
The company's revenue is concentrated in its core operations, with no disclosed segments or geographic breakdowns provided in the available data. This suggests a relatively undiversified revenue stream, which could pose a concentration risk if the core operations face any disruption.
The company's growth trajectory is positive, with a strong revenue base of 76,061,680 and consistent profitability. While no specific growth rates are provided, the company's free cash flow and operating cash flow suggest a capacity for reinvestment and expansion.
Risk factors are minimal, with low liquidity and dilution risk identified. The debt-to-equity ratio of 0.01 indicates a conservative capital structure, and no immediate filing-based liquidity or dilution flags were detected. The dilution potential is also low, with no near-term pressure expected.
Recent events, including filings and transcripts, do not indicate any significant changes or risks to the company's operations. The company's financial health and operational performance remain stable, with no major disruptions reported in the latest available data.
- The company has a strong liquidity position, supported by a high current ratio and substantial cash reserves.
- Profitability metrics are robust, with high return on equity and return on assets.
- The company's revenue is concentrated in its core operations, which may pose a concentration risk.
- Growth is supported by strong cash flow and a conservative capital structure.
- Risk factors are minimal, with low liquidity and dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 9544.SE Market data — financials · 2026-05-27